8-K
WEST PHARMACEUTICAL SERVICES INC (WST)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) – October 23, 2025
| WEST PHARMACEUTICAL SERVICES, INC. |
|---|
(Exact name of registrant as specified in its charter)
| Pennsylvania | 1-8036 | 23-1210010 |
|---|---|---|
| (State or other jurisdiction<br><br>of incorporation) | (Commission File Number) | (IRS Employer<br><br>Identification No.) |
| 530 Herman O. West Drive, Exton, PA | 19341-1147 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: 610-594-2900
| Not Applicable |
|---|
| (Former name or address, if changed since last report.) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||
|---|---|---|---|---|
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||
| --- | --- | ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| --- | --- | ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |
| --- | --- |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of each exchange on which registered |
|---|---|---|
| Common Stock, par value $0.25 per share | WST | New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On October 23, 2025, West Pharmaceutical Services, Inc. (the “Company”) issued a press release announcing its third-quarter 2025 financial results. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Item 7.01 Regulation FD Disclosure.
The information set forth in “Item 2.02 Results of Operations and Financial Condition,” including the exhibit referred to therein, is incorporated herein by reference.
A copy of the Company’s presentation materials used during the call will be available through the Investors link at the Company’s website, http://www.westpharma.com, and is also attached hereto as Exhibit 99.2 and incorporated herein by reference.
The information in this report (including the exhibits attached hereto) is being furnished pursuant to Item 2.02 and Item 7.01 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that section, nor will it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific referencing in such filing.
Item 9.01 Financial Statements and Exhibits.
| (d) | Exhibit No. | Description |
|---|---|---|
| 99.1 | West Pharmaceutical Services, Inc. Press Release, dated October 23, 2025. | |
| 99.2 | West Pharmaceutical Services, Inc. Presentation, dated October 23, 2025. | |
| 104 | The cover page from the Company’s Current Report on Form 8-K, dated October 23, 2025, formatted in Inline XBRL. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| WEST PHARMACEUTICAL SERVICES, INC. | |
|---|---|
| /s/ Robert W. McMahon | |
| Robert W. McMahon | |
| Senior Vice President, Chief Financial Officer | |
| October 23, 2025 |
EXHIBIT INDEX
| Exhibit No. | Description |
|---|---|
| 99.1 | West Pharmaceutical Services, Inc. Press Release, datedOctober 23, 2025. |
| 99.2 | West Pharmaceutical Services, Inc. Presentation, datedOctober 23, 2025. |
| 104 | The cover page from the Company’s Current Report on Form 8-K, dated October 23, 2025, formatted in Inline XBRL. |
4
Document
Exhibit 99.1
West Reports Third-Quarter 2025 Results
Delivered solid growth across Proprietary Products and Contract Manufacturing Segments -
Achieved double-digit growth in HVP Components -
Strengthened executive leadership team, including recently appointed CFO Robert McMahon -
Increases Full-Year 2025 Revenue and EPS Guidance -
Exton, PA, October 23, 2025 – West Pharmaceutical Services, Inc. (NYSE: WST), a leading provider of innovative, high-quality injectable solutions and services, today announced its financial results for the third quarter of 2025.
Third-Quarter Summary (comparisons to prior-year period)
•Net sales of $804.6 million increased 7.7%; organic growth was 5.0%.
•Diluted EPS of $1.92, compared to $1.85 in the same period last year.
•Adjusted-diluted EPS of $1.96, compared to $1.85 in the same period last year.
•Full-year 2025 net sales guidance increased to a range of $3.060 billion to $3.070 billion, up from $3.040 billion to $3.060 billion.
•Full-year 2025 adjusted-diluted EPS guidance increased to a range of $7.06 to $7.11, up from $6.65 to $6.85.
Eric M. Green, President, Chief Executive Officer and Chair of the Board, commented: “I am pleased to report that we delivered another solid quarter, with both revenues and profits exceeding our guidance. Our strength was broad-based, across both our Proprietary Products and Contract Manufacturing segments. We achieved double-digit growth in our HVP Components business, driven by our continued execution in GLP-1 products, increased HVP conversion, including Annex 1, and an overall improving demand environment. As a result of the solid performance in the quarter, and the ongoing momentum in our business, we are again increasing our full-year guidance expectations.”
Proprietary Products Segment
Net sales of $647.5 million grew by 7.7% and increased 5.1% on an organic basis.
•High-Value Product ("HVP") Components net sales of $390.0 million increased 16.3% and rose 13.3% on an organic basis driven by strength in Westar® and Envision® products. HVP Components accounted for 48% of total company net sales in the quarter.
•HVP Delivery Devices net sales of $99.1 million decreased by 15.7%, and were down 16.7% on an organic basis, driven by the previously disclosed one-time incentive fee of approximately $19 million earned in the third quarter of 2024. HVP Delivery Devices accounted for 12% of total company net sales in the quarter.
•Standard Products net sales of $158.4 million increased by 6.7% and rose 3.6% on an organic basis. Standard Products accounted for 20% of total company net sales this quarter.
Contract-Manufactured Products Segment
Net sales of $157.1 million increased by 8.0% and rose 4.9% on an organic basis. Segment performance was driven by an increase in sales of self-injection devices for obesity and diabetes, which was partially offset by a decrease in sales of healthcare diagnostic devices. Contract-Manufactured Products accounted for 20% of total company net sales in the quarter.
Additional Financial Highlights (first nine months of 2025)
Operating cash flow was $503.7 million, an increase of 8.7% over the same period last year. Capital expenditures were $209.8 million, a decrease of 22.9% over the same period last year. Free cash flow (defined as operating cash flow minus capital expenditures) was $293.9 million, an increase of 53.7% over the same period last year.
During the first nine months of 2025, the Company repurchased 552,593 shares for $134.0 million at an average share price of $242.55 under its share repurchase program.
Full-Year 2025 Financial Guidance
•The Company is increasing its full-year 2025 net sales guidance range to $3.060 billion to $3.070 billion, up from $3.040 billion to $3.060 billion.
◦Reported net sales growth anticipated to be in the range of 5.8% to 6.1%, organic net sales growth is expected to be in the range of 3.75% to 4.0%, up from the previous guidance range of 3.0% to 3.75%.
◦Net sales guidance includes an estimated benefit of approximately $59 million based on current foreign currency exchange rates.
•The Company is increasing its full-year 2025 adjusted-diluted EPS guidance range to $7.06 to $7.11, up from the previous range of $6.65 to $6.85.
◦Adjusted-diluted EPS guidance assumes a $0.27 benefit based on current foreign exchange rates, unchanged from previous guidance.
◦This guidance includes EPS of $0.05 associated with tax benefits from stock-based compensation during the first-nine months 2025.
•Capital spending guidance is unchanged at $275 million.
Fourth-Quarter 2025 Financial Guidance
•The Company is introducing its fourth-quarter 2025 net sales guidance range of $790 million to $800 million.
◦Reported net sales growth anticipated to be in the range of 5.5% to 6.8%, organic net sales growth is expected to be in the range of 1.0% to 2.3%.
◦Net sales guidance includes an estimated benefit of approximately $35 million based on current foreign currency exchange rates.
•The Company is introducing its fourth-quarter 2025 adjusted-diluted EPS guidance range of $1.81 to $1.86.
◦Adjusted-diluted EPS guidance assumes a $0.14 benefit based on current foreign exchange rates.
◦Our adjusted-diluted EPS guidance range assumes a tax rate of approximately 21% and does not include potential tax benefits from stock-based compensation.
Third-Quarter 2025 Conference Call
Management will host a conference call at 8 a.m. EDT today. The live webcast can be accessed in the "Investors" section of the Company's website at https://investor.westpharma.com.
To participate in the Q&A portion of the conference call, please register in advance at
https://register-conf.media-server.com/register/BI7b0df3d135614e09b644d37a44c9e15c.
Registered telephone participants will receive the dial-in number along with a unique PIN number that will enable them to ask questions on the call.
An accompanying slide presentation will be posted in the "Investors" section of the Company's website.
A replay of the webcast will be available on the Company's website for approximately 90 days after the event.
| Investor Contact: | Media Contact: |
|---|---|
| John Sweeney, CFA | Michele Polinsky |
| Vice President, Investor Relations | Vice President, Global Communications |
| (484) 790-0373 | (610) 594-3054 |
| John.Sweeney@westpharma.com | Michele.Polinsky@westpharma.com |
About West
West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With over 10,000 team members across 50 sites including 25 manufacturing facilities worldwide, West helps support our customers by delivering over 41 billion components and devices each year. Headquartered in Exton, Pennsylvania, West in its fiscal year 2024 generated $2.89 billion in net sales. West is traded on the New York Stock Exchange (NYSE: WST) and is included in the Standard & Poor's 500 index. For more information, visit www.westpharma.com.
All trademarks and registered trademarks used in this release are the property of West Pharmaceutical Services, Inc. or its subsidiaries, in the United States and other jurisdictions, unless otherwise noted.
Daikyo®, Daikyo Crystal Zenith® and Daikyo CZ® are registered trademarks of Daikyo Seiko, Ltd. Daikyo Crystal Zenith technologies are licensed from Daikyo Seiko, Ltd.
Forward-Looking Statements
This release contains statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may include such words as “raising,” “positioned,” “updating,” “expected,” “assumes,” “unchanged,” “includes,” “would,” “provide," "anticipated" and other similar terminology. These statements reflect management’s current expectations regarding future events, expected tax rates, impacts of tariffs, and operating performance and speak only as of the date of this release. There is no certainty that actual results will be achieved in-line with current expectations. These forward-looking statements involve a number of risks and uncertainties. The following are some of the factors that could cause our actual results to differ materially from those expressed in or underlying our forward-looking statements: prevailing economic conditions and general uncertainties relating thereto that may be unknown and unforeseeable; customers’ changing inventory requirements and manufacturing plans and customer decisions to move forward with our new products and product categories; disruptions or limitations in the Company’s manufacturing capacity; average profitability, or mix, of the products we sell; dependence on third-party suppliers and partners; increased raw material, energy and labor costs; fluctuations in currency exchange; the ability to meet development milestones with key customers; and the consequences of other geopolitical events, including tariffs, natural disasters, acts of war, and global health crises. This list of important factors is not all inclusive. For a description of certain additional factors that could cause the Company’s future results to differ from those expressed in any such forward-looking statements, see Part I Item 1A, entitled “Risk Factors,” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, and other filings with the United States Securities and Exchange Commission, including the Company’s quarterly reports on Form 10-Q and current reports on Form 8-K. The Company does not undertake to update these forward-looking statements.
Except as required by law or regulation, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
Non-U.S. GAAP Financial Measures
This release contains certain non-GAAP financial measures. For the purpose of aiding the comparison of our year-over-year results, we may refer to net sales and other financial results excluding the effects of changes in foreign currency exchange rates. Organic net sales exclude the impact from acquisitions and/or divestitures and translate the current-period reported sales of subsidiaries whose functional currency is other than the U.S. Dollar at the applicable foreign currency exchange rates in effect during the comparable prior-year period. We may also refer to financial results excluding the effects of unallocated items. The re-measured results excluding effects from currency translation and excluding the effects of unallocated items are not in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) and should not be used as a substitute for the comparable U.S. GAAP financial measures. The non-U.S. GAAP financial measures are incorporated into our discussion and analysis as management uses them in evaluating our results of operations and believes that this information provides users a valuable insight into our overall performance and financial position. A reconciliation of these adjusted non-U.S. GAAP measures to the comparable U.S. GAAP financial measures is included in the accompanying tables.
WEST PHARMACEUTICAL SERVICES, INC.
CONSOLIDATED STATEMENTS OF INCOME
(UNAUDITED)
(in millions, except per share data)
| Three Months Ended<br>September 30, | Nine Months Ended<br>September 30, | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |||||||||
| Net sales | $ | 804.6 | 100% | $ | 746.9 | 100% | $ | 2,269.1 | 100% | $ | 2,144.4 | 100% |
| Cost of goods and services sold | 510.3 | 63 | 482.2 | 65 | 1,469.0 | 65 | 1,419.5 | 66 | ||||
| Gross profit | 294.3 | 37 | 264.7 | 35 | 800.1 | 35 | 724.9 | 34 | ||||
| Research and development | 17.1 | 2 | 15.5 | 2 | 52.5 | 2 | 50.6 | 2 | ||||
| Selling, general and administrative expenses | 102.7 | 13 | 83.5 | 11 | 286.6 | 13 | 253.2 | 12 | ||||
| Other expense (income), net | 6.9 | 1 | 4.4 | 1 | 32.7 | 1 | 10.8 | 1 | ||||
| Operating profit | 167.6 | 21 | 161.3 | 21 | 428.3 | 19 | 410.3 | 19 | ||||
| Interest (income) expense, net | (4.5) | — | (3.9) | (1) | (11.7) | — | (11.0) | (1) | ||||
| Other nonoperating expense (income) | 0.2 | — | 0.7 | — | 0.6 | — | 0.7 | — | ||||
| Income before income taxes and equity in net income of affiliated companies | 171.9 | 21 | 164.5 | 22 | 439.4 | 19 | 420.6 | 20 | ||||
| Income tax expense | 34.0 | 4 | 32.4 | 4 | 88.3 | 4 | 70.7 | 3 | ||||
| Equity in net income of affiliated companies | (2.1) | — | (3.9) | — | (10.5) | (1) | (12.7) | — | ||||
| Net income | $ | 140.0 | 17% | $ | 136.0 | 18% | $ | 361.6 | 16% | $ | 362.6 | 17% |
| Net income per share: | ||||||||||||
| Basic | $ | 1.94 | $ | 1.87 | $ | 5.00 | $ | 4.96 | ||||
| Diluted | $ | 1.92 | $ | 1.85 | $ | 4.97 | $ | 4.91 | ||||
| Average common shares outstanding | 72.2 | 72.8 | 72.3 | 73.1 | ||||||||
| Average shares assuming dilution | 72.6 | 73.4 | 72.7 | 73.8 |
WEST PHARMACEUTICAL SERVICES
REPORTING SEGMENT INFORMATION
(UNAUDITED)
(in millions)
| Three Months Ended<br>September 30, | Nine Months Ended<br>September 30, | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales: | 2025 | 2024 | 2025 | 2024 | ||||||||
| Proprietary Products | $ | 647.5 | $ | 601.4 | $ | 1,830.3 | $ | 1,720.6 | ||||
| Contract-Manufactured Products | 157.1 | 145.5 | 438.8 | 423.8 | ||||||||
| Consolidated Total | $ | 804.6 | $ | 746.9 | $ | 2,269.1 | $ | 2,144.4 | ||||
| Gross Profit: | ||||||||||||
| Proprietary Products | $ | 264.0 | $ | 235.7 | $ | 722.5 | $ | 649.8 | ||||
| Contract-Manufactured Products | 30.3 | 29.0 | 77.6 | 75.1 | ||||||||
| Gross Profit | $ | 294.3 | $ | 264.7 | $ | 800.1 | $ | 724.9 | ||||
| Gross Profit Margin | 36.6 | % | 35.4 | % | 35.3 | % | 33.8 | % | ||||
| Operating Profit (Loss): | ||||||||||||
| Proprietary Products | $ | 175.2 | $ | 158.2 | $ | 467.5 | $ | 415.5 | ||||
| Contract-Manufactured Products | 22.3 | 21.8 | 53.6 | 56.1 | ||||||||
| Stock-based compensation expense | (8.4) | (5.1) | (17.1) | (14.4) | ||||||||
| General corporate costs | (21.5) | (13.6) | (75.7) | (46.9) | ||||||||
| Reported Operating Profit | $ | 167.6 | $ | 161.3 | $ | 428.3 | $ | 410.3 | ||||
| Reported Operating Profit Margin | 20.8 | % | 21.6 | % | 18.9 | % | 19.1 | % | ||||
| Unallocated items | 2.5 | (0.7) | 22.1 | (0.3) | ||||||||
| Adjusted Operating Profit | $ | 170.1 | $ | 160.6 | $ | 450.4 | $ | 410.0 | ||||
| Adjusted Operating Profit Margin | 21.1 | % | 21.5 | % | 19.8 | % | 19.1 | % |
WEST PHARMACEUTICAL SERVICES
RECONCILIATION OF NON-U.S. GAAP MEASURES (UNAUDITED)
Please refer to “Non-U.S. GAAP Financial Measures” for more information
(in millions, except per share data)
Reconciliation of Reported and Adjusted Operating Profit, Net Income and Diluted EPS
| Three Months ended September 30, 2025 | Operating<br>profit | Income<br>tax<br>expense | Net<br>income | Diluted<br>EPS |
|---|---|---|---|---|
| Reported (U.S. GAAP) | $167.6 | $34.0 | $140.0 | $1.92 |
| Unallocated Items: | ||||
| Restructuring and other charges (1) | 2.5 | 0.6 | 2.0 | 0.03 |
| Amortization of acquisition-related intangible assets (2) | — | — | 0.4 | 0.01 |
| Adjusted (Non-U.S. GAAP) | $170.1 | $34.6 | $142.4 | $1.96 |
| Nine Months ended September 30, 2025 | Operating<br>profit | Income<br>tax<br>expense | Net<br>income | Diluted<br>EPS |
| --- | --- | --- | --- | --- |
| Reported (U.S. GAAP) | $428.3 | $88.3 | $361.6 | $4.97 |
| Unallocated Items: | ||||
| Restructuring and other charges (1) | 21.9 | 3.0 | 19.0 | 0.26 |
| Amortization of acquisition-related intangible assets (2) | 0.2 | — | 1.5 | 0.02 |
| Adjusted (Non-U.S. GAAP) | $450.4 | $91.3 | $382.1 | $5.25 |
| Three Months ended September 30, 2024 | Operating<br>profit | Income<br>tax<br>expense | Net<br>income | Diluted<br>EPS |
| --- | --- | --- | --- | --- |
| Reported (U.S. GAAP) | $161.3 | $32.4 | $136.0 | $1.85 |
| Unallocated items: | ||||
| Restructuring and other charges (1) | (0.9) | (0.3) | (0.6) | (0.01) |
| Amortization of acquisition-related intangible assets (2) | 0.2 | 0.1 | 0.7 | 0.01 |
| Adjusted (Non-U.S. GAAP) | $160.6 | $32.2 | $136.1 | $1.85 |
| Nine Months ended September 30, 2024 | Operating<br>profit | Income<br>tax<br>expense | Net<br>income | Diluted<br>EPS |
| --- | --- | --- | --- | --- |
| Reported (U.S. GAAP) | $410.3 | $70.7 | $362.6 | $4.91 |
| Unallocated items: | ||||
| Restructuring and other charges (1) | (0.9) | (0.3) | (0.6) | (0.01) |
| Amortization of acquisition-related intangible assets (2) | 0.6 | 0.1 | 2.1 | 0.03 |
| Adjusted (Non-U.S. GAAP) | $410.0 | $70.5 | $364.1 | $4.93 |
(1)During the three and nine months ended September 30, 2025, the Company recorded charges of $2.5 million and $21.9 million, respectively, related to restructuring programs. During the three and nine months ended September 30, 2025, the Company recorded $0.9 million and $17.5 million, respectively, of the charges within other expense (income), related to severance and acceleration of depreciation and lease costs in connection with the Company's 2025 restructuring plan. The Company recorded the remaining $1.6 million and $4.4 million, respectively, within selling, general and administrative expenses, related to our plan to optimize the legal structure of the Company and its subsidiaries. Restructuring and other charges were a net benefit $0.9 million for the three and nine months ended September 30, 2024. The net benefit represented the impact of two items, the first of which is a $2.5 million benefit recorded within other expense (income) related to revised severance estimates in connection with the Company's 2022 restructuring plan. This benefit was partially offset by $1.6 million of expense recorded within selling, general and administrative expenses, related to our plan to optimize the legal structure of the Company and its subsidiaries.
(2)During the nine months ended September 30, 2025, the Company recorded $0.2 million of amortization expense within operating profit associated with an intangible asset acquired during the second quarter of 2020. During the three and nine months ended September 30, 2025, the Company recorded $0.4 million and $1.3 million, respectively, of amortization expense in association with an acquisition of increased ownership interest in Daikyo. During the three and nine months ended September 30, 2024, the Company recorded $0.2 million and $0.6 million, respectively, of amortization expense within operating profit associated with an intangible asset acquired during the second quarter of 2020. During the three and nine months ended September 30, 2024, the Company recorded $0.6 million and $1.6 million, respectively, of amortization expense in association with an acquisition of increased ownership interest in Daikyo.
WEST PHARMACEUTICAL SERVICES
RECONCILIATION OF NON-U.S. GAAP FINANCIAL MEASURES (UNAUDITED)
Please refer to “Non-U.S. GAAP Financial Measures” for more information
(in millions, except per share data)
Reconciliation of Reported Net Sales to Organic Net Sales by Segment (3)
| Three Months ended September 30, | Reported Net Sales (U.S. GAAP) | Percent Change | Impact of Currency | Organic Net Sales Growth Rate (Decline) (Non-U.S. GAAP) (3) | |||||
|---|---|---|---|---|---|---|---|---|---|
| 2025 | |||||||||
| Proprietary Products | 647.5 | $601.4 | 7.7 | % | 2.6 | % | 5.1 | % | |
| Contract-Manufactured Products | 157.1 | 145.5 | 8.0 | % | 3.1 | % | 4.9 | % | |
| Total | 804.6 | $746.9 | 7.7 | % | 2.7 | % | 5.0 | % |
All values are in US Dollars.
| Nine Months ended September 30, | Reported Net Sales (U.S. GAAP) | Percent Change | Impact of Currency | Organic Net Sales Growth Rate (Decline) (Non-U.S. GAAP) (3) | |||||
|---|---|---|---|---|---|---|---|---|---|
| 2025 | |||||||||
| Proprietary Products | 1,830.3 | $1,720.6 | 6.4 | % | 1.1 | % | 5.3 | % | |
| Contract-Manufactured Products | 438.8 | 423.8 | 3.5 | % | 1.4 | % | 2.1 | % | |
| Total | 2,269.1 | $2,144.4 | 5.8 | % | 1.1 | % | 4.7 | % |
All values are in US Dollars.
Reconciliation of Proprietary Products Segment Organic Net Sales by Product Category (3)
| Three Months ended September 30, | Reported Net Sales (U.S. GAAP) | Percent Change | Impact of Currency | Organic Net Sales Growth Rate (Decline) (Non-U.S. GAAP) (3) | |||||
|---|---|---|---|---|---|---|---|---|---|
| 2025 | |||||||||
| HVP Components | 390.0 | $335.4 | 16.3 | % | 3.0 | % | 13.3 | % | |
| HVP Delivery Devices | 99.1 | 117.5 | (15.7) | % | 1.0 | % | (16.7) | % | |
| Standard Products | 158.4 | 148.5 | 6.7 | % | 3.1 | % | 3.6 | % | |
| Total Proprietary Products | 647.5 | $601.4 | 7.7 | % | 2.6 | % | 5.1 | % |
All values are in US Dollars.
| Nine Months ended September 30, | Reported Net Sales (U.S. GAAP) | Percent Change | Impact of Currency | Organic Net Sales Growth Rate (Decline) (Non-U.S. GAAP) (3) | |||||
|---|---|---|---|---|---|---|---|---|---|
| 2025 | |||||||||
| HVP Components | 1,061.2 | $980.9 | 8.2 | % | 1.3 | % | 6.9 | % | |
| HVP Delivery Devices | 296.0 | 271.6 | 9.0 | % | 0.6 | % | 8.4 | % | |
| Standard Products | 473.1 | 468.1 | 1.1 | % | 0.9 | % | 0.2 | % | |
| Total Proprietary Products | 1,830.3 | $1,720.6 | 6.4 | % | 1.1 | % | 5.3 | % |
All values are in US Dollars.
Reconciliation of Proprietary Products Segment Organic Net Sales by Market Group (3)
| Three Months ended September 30, | Reported Net Sales (U.S. GAAP) | Percent Change | Impact of Currency | Organic Net Sales Growth Rate (Decline) (Non-U.S. GAAP) (3) | |||||
|---|---|---|---|---|---|---|---|---|---|
| 2025 | |||||||||
| Biologics | 329.1 | $296.4 | 11.0 | % | 2.7 | % | 8.3 | % | |
| Pharma | 182.5 | 174.3 | 4.7 | % | 3.3 | % | 1.4 | % | |
| Generics | 135.9 | 130.7 | 4.0 | % | 1.4 | % | 2.6 | % | |
| Total Proprietary Products | 647.5 | $601.4 | 7.7 | % | 2.6 | % | 5.1 | % |
All values are in US Dollars.
| Nine Months ended September 30, | Reported Net Sales (U.S. GAAP) | Percent Change | Impact of Currency | Organic Net Sales Growth Rate (Decline) (Non-U.S. GAAP) (3) | |||||
|---|---|---|---|---|---|---|---|---|---|
| 2025 | |||||||||
| Biologics | 886.1 | $811.4 | 9.2 | % | 1.4 | % | 7.8 | % | |
| Pharma | 561.6 | 530.8 | 5.8 | % | 1.4 | % | 4.4 | % | |
| Generics | 382.6 | 378.4 | 1.1 | % | — | % | 1.1 | % | |
| Total Proprietary Products | 1,830.3 | $1,720.6 | 6.4 | % | 1.1 | % | 5.3 | % |
All values are in US Dollars.
Reconciliation of Reported Net Sales to Organic Net Sales by Geography (3)
| Three Months ended September 30, | Reported Net Sales (U.S. GAAP) | Percent Change | Impact of Currency | Organic Net Sales Growth Rate (Decline) (Non-U.S. GAAP) (3) | |||||
|---|---|---|---|---|---|---|---|---|---|
| 2025 | |||||||||
| Americas | 375.3 | $356.5 | 5.3 | % | 0.1 | % | 5.2 | % | |
| Europe, Middle East, Africa | 361.1 | 330.1 | 9.4 | % | 6.3 | % | 3.1 | % | |
| Asia Pacific | 68.2 | 60.3 | 13.1 | % | (1.8) | % | 14.9 | % | |
| Total | 804.6 | $746.9 | 7.7 | % | 2.7 | % | 5.0 | % |
All values are in US Dollars.
| Nine Months ended September 30, | Reported Net Sales (U.S. GAAP) | Percent Change | Impact of Currency | Organic Net Sales Growth Rate (Decline) (Non-U.S. GAAP) (3) | |||||
|---|---|---|---|---|---|---|---|---|---|
| 2025 | |||||||||
| Americas | 1,063.9 | $957.1 | 11.2 | % | (0.3) | % | 11.5 | % | |
| Europe, Middle East, Africa | 1,017.7 | 1,000.5 | 1.7 | % | 3.1 | % | (1.4) | % | |
| Asia Pacific | 187.5 | 186.8 | 0.4 | % | (1.7) | % | 2.1 | % | |
| Total | 2,269.1 | $2,144.4 | 5.8 | % | 1.1 | % | 4.7 | % |
All values are in US Dollars.
(3)Organic net sales exclude the impact from acquisitions and/or divestitures and translate the current-period reported sales of subsidiaries whose functional currency is other than the U.S. Dollar at the applicable foreign currency exchange rates in effect during the comparable prior-year period.
WEST PHARMACEUTICAL SERVICES
RECONCILIATION OF NON-U.S. GAAP FINANCIAL MEASURES (UNAUDITED)
Please refer to “Non-U.S. GAAP Financial Measures” for more information
(in millions, except per share data)
Reconciliation of Reported-Diluted EPS Guidance to Adjusted-Diluted EPS Guidance
| 2024 Actual | 2025 Guidance | % Change | |
|---|---|---|---|
| Reported-diluted EPS (U.S. GAAP) | $6.69 | $6.75 to $6.80 | 0.9% to 1.6% |
| Restructuring and other charges | 0.02 | 0.28 | |
| Amortization of acquisition-related intangible assets | 0.04 | 0.03 | |
| Adjusted-diluted EPS (Non-U.S. GAAP) (4) | $6.75 | $7.06 to $7.11 | 4.6% to 5.3% |
(4)We have opted not to forecast 2025 tax benefits from stock-based compensation in the fourth quarter, as they are out of the Company’s control. Instead, we recognize the benefits as they occur. In the first nine months of 2025, tax benefits associated with stock-based compensation increased adjusted-diluted EPS by $0.05. Any future tax benefits associated with stock-based compensation that we receive in 2025 would provide a positive adjustment to our full-year EPS guidance. In full-year 2024, tax benefits associated with stock-based compensation increased adjusted-diluted EPS by $0.26. See “Full-year 2025 Financial Guidance” and “Non-U.S. GAAP Financial Measures” in today’s press release for additional information regarding adjusted-diluted EPS.
WEST PHARMACEUTICAL SERVICES
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
| (in millions, except per share data) | September 30,<br>2025 | December 31,<br>2024 | ||
|---|---|---|---|---|
| ASSETS | ||||
| Current assets: | ||||
| Cash and cash equivalents | $ | 628.5 | $ | 484.6 |
| Accounts receivable, net | 625.0 | 552.5 | ||
| Inventories | 438.0 | 377.0 | ||
| Other current assets | 131.8 | 124.0 | ||
| Total current assets | 1,823.3 | 1,538.1 | ||
| Property, plant and equipment | 3,232.9 | 2,985.8 | ||
| Less: accumulated depreciation and amortization | 1,492.3 | 1,404.2 | ||
| Property, plant and equipment, net | 1,740.6 | 1,581.6 | ||
| Operating lease right-of-use assets | 97.8 | 104.5 | ||
| Investments in affiliated companies | 220.9 | 202.1 | ||
| Goodwill | 110.6 | 106.0 | ||
| Intangible assets, net | 8.9 | 10.8 | ||
| Deferred income taxes | 27.9 | 26.0 | ||
| Other noncurrent assets | 75.8 | 74.3 | ||
| Total Assets | $ | 4,105.8 | $ | 3,643.4 |
| LIABILITIES AND EQUITY | ||||
| Current liabilities: | ||||
| Accounts payable | $ | 255.8 | $ | 239.3 |
| Accrued salaries, wages and benefits | 111.8 | 73.5 | ||
| Income taxes payable | 33.3 | 31.5 | ||
| Operating lease liabilities | 21.4 | 17.9 | ||
| Other current liabilities | 213.1 | 188.2 | ||
| Total current liabilities | 635.4 | 550.4 | ||
| Long-term debt | 202.7 | 202.6 | ||
| Deferred income taxes | 22.8 | 20.5 | ||
| Pension and other postretirement benefits | 31.1 | 28.2 | ||
| Operating lease liabilities | 73.5 | 81.8 | ||
| Deferred compensation benefits | 13.5 | 15.4 | ||
| Other long-term liabilities | 75.3 | 62.2 | ||
| Total Liabilities | 1,054.3 | 961.1 | ||
| Equity: | ||||
| Preferred stock, 3.0 million shares authorized; 0 shares issued and outstanding | — | — | ||
| Common stock, par value $0.25 per share; 200.0 million shares authorized; shares issued: September 30, 2025 - 75.3 million, December 31, 2024 - 75.3 million; shares outstanding: September 30, 2025 - 71.9 million, December 31, 2024 - 72.3 million | 18.8 | 18.8 | ||
| Capital in excess of par value | — | 22.1 | ||
| Retained earnings | 4,262.4 | 3,956.6 | ||
| Accumulated other comprehensive loss | (102.3) | (258.1) | ||
| Treasury stock, at cost (September 30, 2025 - 3.4 million shares, December 31, 2024 - 3.0 million shares) | (1,127.4) | (1,057.1) | ||
| Total Equity | 3,051.5 | 2,682.3 | ||
| Total Liabilities and Equity | $ | 4,105.8 | $ | 3,643.4 |
WEST PHARMACEUTICAL SERVICES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
(in millions)
| Nine Months Ended<br>September 30, | ||||
|---|---|---|---|---|
| 2025 | 2024 | |||
| Cash flows from operating activities: | ||||
| Net income | $ | 361.6 | $ | 362.6 |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation | 122.2 | 112.0 | ||
| Amortization | 2.2 | 2.7 | ||
| Stock-based compensation | 17.1 | 14.4 | ||
| Non-cash restructuring charges | 2.5 | — | ||
| Asset impairments | 4.4 | 1.9 | ||
| Other non-cash items, net | (4.4) | (9.7) | ||
| Changes in assets and liabilities | (1.9) | (20.6) | ||
| Net cash provided by operating activities | 503.7 | 463.3 | ||
| Cash flows from investing activities: | ||||
| Capital expenditures | (209.8) | (272.1) | ||
| Other, net | — | (1.8) | ||
| Net cash used in investing activities | (209.8) | (273.9) | ||
| Cash flows from financing activities: | ||||
| Borrowings of long-term debt | — | 164.7 | ||
| Repayments of long-term debt | — | (169.0) | ||
| Principal repayments on finance leases | (0.8) | (23.2) | ||
| Excise tax payments | (4.2) | — | ||
| Dividend payments | (45.4) | (43.8) | ||
| Proceeds from stock-based compensation awards | 8.2 | 24.0 | ||
| Employee stock purchase plan contributions | 5.4 | 5.6 | ||
| Shares purchased under share repurchase programs | (134.0) | (506.5) | ||
| Shares repurchased for employee tax withholdings | (2.6) | (5.5) | ||
| Net cash used in financing activities | (173.4) | (553.7) | ||
| Effect of exchange rates on cash | 23.4 | 1.3 | ||
| Net increase (decrease) in cash and cash equivalents | 143.9 | (363.0) | ||
| Cash, including cash equivalents at beginning of period | 484.6 | 853.9 | ||
| Cash, including cash equivalents at end of period | $ | 628.5 | $ | 490.9 |
| Supplemental cash flow information: | ||||
| Accrued capital expenditures | $ | 38.1 | $ | 50.3 |
a3q25earningspresentatio
West Pharmaceutical Services, Inc. Eric M. Green President & CEO, Chair of the Board Bob W. McMahon Senior VP & Chief Financial Officer Third-Quarter 2025 Earnings Call October 23, 2025 | 8 a.m. Eastern Time
2 West Analyst Conference Call October 23, 2025 8 a.m. Eastern Time These presentation materials are intended to accompany and serve as a reference for today’s press release announcing the Company’s results for the third quarter 2025 and management’s discussion of those results during today’s conference call. A webcast of today’s call can be accessed in the “Investors” section of the Company’s website at www.investor.westpharma.com. To participate on the call by asking questions to Management, please register in advance by clicking here. Registered telephone participants will receive the dial-in number along with a unique PIN number that will enable them to ask questions on the call. A replay of the webcast will be available on the Company’s website for approximately 90 days after the event. REGISTER TODAY
3 Safe Harbor Statement This presentation and any accompanying management commentary contain “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about product development, operational performance and expectations regarding future events. Each of these statements is based on preliminary information, and actual results could differ from any preliminary estimates. We caution investors that the risk factors listed under our “Forward Looking Statements” in our press releases, as well as those set forth under the caption "Risk Factors" in our most recent Annual Report on Form 10-K as filed with the Securities and Exchange Commission and as revised or supplemented by our quarterly reports on Form 10-Q, could cause our actual results to differ materially from those estimated or predicted in the forward-looking statements. You should evaluate any statement in light of these important factors. Except as required by law or regulation, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, therefore you should not rely on these forward-looking statements as representing our views as of any date other than today. Certain financial measures included in these presentation materials, or which may be referred to in management’s discussion of the Company’s results and outlook, have not been calculated in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”), and therefore are referred to as non-U.S. GAAP financial measures. Non-U.S. GAAP financial measures should not be considered in isolation or as an alternative to such measures determined in accordance with U.S. GAAP. Please refer to “Non-U.S. GAAP Financial Measures” and the accompanying tables at the end of this presentation for more information. Cautionary Statement Under the Private Securities Litigation Reform Act of 1995 Non-U.S. GAAP Financial Measures Trademarks and registered trademarks used in this report are the property of West Pharmaceutical Services, Inc. or its subsidiaries, in the United States and other jurisdictions, unless noted otherwise. Daikyo Crystal Zenith® and Daikyo CZ® are registered trademarks of Daikyo Seiko, Ltd. Daikyo Crystal Zenith technologies are licensed from Daikyo Seiko, Ltd. Trademarks
4 • Net sales $804.6M, +7.7% & +5.0% organic(1) o $19 million, one-time incentive fee in PY reduced organic growth by 2.8% • Gross margin 36.6%, +120 bps YoY • Adjusted operating profit margin(1) 21.1%, -40 bps vs. 3Q24 o $19 million, one-time incentive fee in PY negatively impacted YoY OP margin expansion by 200 bps • Adj-diluted EPS(1) of $1.96, +5.9% vs. 3Q24 • 9M25 Operating cash flow $503.7M, +8.7% YoY • 9M25 Cap ex of $209.8M, -22.9% YoY • 9M25 Free cash flow(1) $293.9M, +53.7% YoY "Organic Net Sales," “Adjusted Operating Profit,” “Adjusted Operating Profit Margin,” “Adjusted-Diluted EPS” and "Free Cash Flow" are Non-U.S. GAAP financial measures. See accompanying slides and the discussion under the heading “Non-U.S. GAAP Financial Measures” in today’s press release for an explanation and reconciliation of these items. (1) 3Q25 Financial Highlights 21.5% 21.1% 3Q24 3Q25 $1.85 $1.96 3Q24 3Q25 $746.9 $804.6 3Q24 3Q25 Net Sales $M Adj. OP Margin Adj. Diluted EPS +5.9% YoY-40 bps YoY +7.7% Reported +5.0% Organic
5 Capitalizing on Key Growth Drivers Across Our Business Biologics Expanding market – driving High- Value Products Annex 1 EU regulatory framework upgrade opportunity GLP-1 Fastest growing category, multi-year opportunity – 17% of Net Sales Capacity Expansion Across 8 locations: 4 in U.S; 3 in Europe; 1 in Asia • 41% of West’s revenue in 3Q25 • Fuels mix shift to high-margin HVP • Continued strong participation rate in new drug launches • ~6 billion components potential opportunity moving standard packaging to HVP components • Record 375 Annex 1 on-going upgrade projects. Once projects convert to commercial revenues, no longer included in project list. • Expected to drive 200 bps of revenue in FY25 • GLP-1 elastomers are 9% of 3Q25 total company revenues • GLP-1 Contract Manufacturing revenues are 8% of 3Q25 total company revenues • CM future revenue growth/ margin expansion opportunity from drug handling • Capex aligned to growth opportunities in biologics, Annex 1 and GLP-1 • Network optimization: improving service levels/managing tariff exposure B u sin ess O p p o rtu n ity, Im p act & R esu lts D river
6 Proprietary Products Segment Segment Performance • Proprietary net sales of $647.5M, +7.7% YoY, +5.1% organic • Segment gross profit of 40.8%, +160 bps YoY • Proprietary OP margin of 27.1%, +80 bps YoY. o $19 million one-time incentive fee in PY negatively impacted YoY OP margin expansion by 240 bps Proprietary Products Revenues $M $601.4 $647.5 3Q24 3Q25 3Q25 results Proprietary OP Margin % 26.3% 27.1% 3Q24 3Q25 Net sales $390.0M 48% of total sales +16.3% reported +13.3% organic Net sales $99.1M 12% of total sales -15.7% reported -16.7% organic Net sales $158.4M 20% of total sales +6.7% reported +3.6% organic • HVP components - highest margin business • GLP-1s - strong contributor: 9% of total company sales • Annex 1 - tracking ahead of our expectations – 200 bps of FY25 sales growth • Improving underlying demand for HVP components • $19 million one-time incentive fee in PY reduced organic growth by 16.2 percentage points • Improved economics of this business sequentially every quarter in 2025 • Basic primary containment products - often spec’d into customers’ drug manufacturing processes • Important business funnel forming the base from which West converts to HVP components over time HVP Components HVP Delivery Devices Standard Components
7 Contract Manufacturing Segment Segment Performance • CM net sales of $157.1M, +8.0% YoY & +4.9% organic • Segment gross profit 19.3%, -60 bps YoY • CM OP margin 14.2%, -80 bps YoY Contract Manufacturing Revenues $M $145.5 $157.1 3Q24 3Q25 3Q25 results CM OP Margin % 15.0% 14.2% 3Q24 3Q25 Net sales $157.1M, 20% of total sales, +8.0% reported, +4.9% organic • Ramp of Dublin operations mainly offset the loss of the Arizona-based CGM contract in 2024 • Utilizing Arizona site to consolidate operations from less efficient locations • On track to introduce drug handling and cold storage business in early 2026 Segment Performance
8 Strategically Diversified Platform with Global Reach 1 Quarter ended September 30, 2025 – numbers represent % of total company sales 2 Non-proprietary products 47% Americas 45% Europe, Middle East, Africa Asia Pacific 8% Net Sales1 by Geographic Location 48% HVP Components20% Standard Packaging 12% HVP Delivery Devices Contract-Manufactured Products2 20% Net Sales1 by Product Category 41% Biologics 17% Generics 22% Pharma Net Sales1 by Market Group Contract-Manufactured Products2 20%
9 3Q25 Revenue by Market Group 3Q25 Revenues YoY % chg. Currency % Organic % Share of Total Company Revenue Biologics* $329.1 11.0% 2.7% 8.3% 41% Generics $135.9 4.0% 1.4% 2.6% 17% Pharma $182.5 4.7% 3.3% 1.4% 22% Proprietary Prod. Segment $647.5 7.7% 2.6% 5.1% 80% Contract Man. Segment $157.1 8.0% 3.1% 4.9% 20% Total Company $804.6 7.7% 2.7% 5.0% 100% * $19 million one-time incentive fee in PY reduced organic growth by 7.4 percentage points
10 3Q25 Revenue by Product Category 3Q25 Revenues YoY % chg. Currency % Organic % Share of Total Company Revenue HVP Components $390.0 16.3% 3.0% 13.3% 48% HVP Delivery Devices* $99.1 (15.7)% 1.0% (16.7)% 12% Standard Products $158.4 6.7% 3.1% 3.6% 20% Proprietary Prod. Segment $647.5 7.7% 2.6% 5.1% 80% Contract Man. Segment $157.1 8.0% 3.1% 4.9% 20% Total Company $804.6 7.7% 2.7% 5.0% 100% * $19 million one-time incentive fee in PY reduced organic growth by 16.2 percentage points
11 3Q25 Revenue by Geography 3Q25 Revenues YoY % chg. Currency % Organic % Share of Total Company Revenue Americas $375.3 5.3% 0.1% 5.2% 47% Europe, Middle East, Africa $361.1 9.4% 6.3% 3.1% 45% Asia Pacific $68.2 13.1% (1.8)% 14.9% 8% Total Company $804.6 7.7% 2.7% 5.0% 100%
Change in Consolidated Net Sales 3Q25 vs. 3Q24 ($ millions) $746.9 ($19.0) $12.5 $44.1 $20.1 $804.6 3Q24 PY Customer Incentives CY Sales Price Volume & Mix Fx. Translation 3Q25 12
13* Current Adjusted EPS guidance includes 3Q25 Stock Based Compensation Tax benefit of $0.05 and assumes no additional benefit in 4Q25. Revenue Previous Annual Guidance 4Q25 GuidanceCurrent Annual Guidance Fx. YoY Revenue Impact Organic Revenue Growth % Adjusted EPS* YoY Fx. on Adjusted EPS Tax Benefits from Stock- Based Compensation Estimated Tax Rate Capital Expenditure Low High Low High Low High $3.040B $3.060B 3.0% 3.75% $6.65 $6.85 ~$59M Benefit +$0.27 +$0.04 $275M $3.060B $3.070B 3.75% 4.0% $7.06 $7.11 ~$59M Benefit +$0.27 +$0.05 $275M $790M $800M 1.0% 2.3% $1.81 $1.86 to to to to to to to to to Guidance Overview ~21% ~$35M Benefit +$0.14 ~20.5%~22%
Investor Relations contact: https://investor.westpharma.co m/contact-investor-relations www.westpharma.com
Notes to Non-U.S. GAAP Financial Measures The Non-U.S. GAAP financial measures are incorporated into our discussion and analysis as management uses them in evaluating our results of operations and believes that this information provides users a valuable insight into our overall performance and financial position. A reconciliation of these adjusted Non-U.S. GAAP financial measures to the comparable U.S. GAAP financial measures is included in the accompanying tables and today's press release. For the purpose of aiding the comparison of our year-over-year results, we may refer to net sales and other financial results excluding the effects of changes in foreign currency exchange rates. Organic net sales exclude the impact from acquisitions and/or divestitures and translate the current-period reported sales of subsidiaries whose functional currency is other than the U.S. Dollar at the applicable foreign exchange rates in effect during the comparable prior-year period. We may also refer to financial results excluding the effects of unallocated items. The re-measured results excluding effects from currency translation, the impact from acquisitions and/or divestitures, and the effects of unallocated items are not in conformity with U.S. GAAP and should not be used as a substitute for the comparable U.S. GAAP financial measures.
Notes to Non-U.S. GAAP Financial Measures RECONCILIATION OF NON-U.S. GAAP FINANCIAL MEASURES (UNAUDITED) See “Notes to Non-U.S. GAAP Financial Measures”, “Safe Harbor Statement” (Slide 3) and today’s press release for an explanation and reconciliation of these items. Reconciliation of Reported and Adjusted Operating Profit, Net Income and Diluted EPS ($ millions, except EPS data) Three months ended September 30, 2025 Operating profit Income tax expense Net income Diluted EPS Reported (U.S. GAAP) $167.6 $34.0 $140.0 $1.92 Unallocated items: Restructuring and other charges 2.5 0.6 2.0 0.03 Amortization of acquisition-related intangible assets - - 0.4 0.01 Adjusted (Non-U.S. GAAP) $170.1 $34.6 $142.4 $1.96 Nine months ended September 30, 2025 Operating profit Income tax expense Net income Diluted EPS Reported (U.S. GAAP) $428.3 $88.3 $361.6 $4.97 Unallocated items: Restructuring and other charges 21.9 3.0 19.0 0.26 Amortization of acquisition-related intangible assets 0.2 - 1.5 0.02 Adjusted (Non-U.S. GAAP) $450.4 $91.3 $382.1 $5.25
Notes to Non-U.S. GAAP Financial Measures RECONCILIATION OF NON-U.S. GAAP FINANCIAL MEASURES (UNAUDITED) See “Notes to Non-U.S. GAAP Financial Measures”, “Safe Harbor Statement” (Slide 3) and today’s press release for an explanation and reconciliation of these items. Reconciliation of Reported and Adjusted Operating Profit, Net Income and Diluted EPS ($ millions, except EPS data) Three months ended September 30, 2024 Operating profit Income tax expense Net income Diluted EPS Reported (U.S. GAAP) $161.3 $32.4 $136.0 $1.85 Unallocated items: Restructuring and other charges (0.9) (0.3) (0.6) (0.01) Amortization of acquisition-related intangible assets 0.2 0.1 0.7 0.01 Adjusted (Non-U.S. GAAP) $160.6 $32.2 $136.1 $1.85 Nine months ended September 30, 2024 Operating profit Income tax expense Net income Diluted EPS Reported (U.S. GAAP) $410.3 $70.7 $362.6 $4.91 Unallocated items: Restructuring and other charges (0.9) (0.3) (0.6) (0.01) Amortization of acquisition-related intangible assets 0.6 0.1 2.1 0.03 Adjusted (Non-U.S. GAAP) $410.0 $70.5 $364.1 $4.93
Notes to Non-U.S. GAAP Financial Measures RECONCILIATION OF NON-U.S. GAAP FINANCIAL MEASURES (UNAUDITED) See “Notes to Non-U.S. GAAP Financial Measures”, “Safe Harbor Statement” (Slide 3) and today’s press release for an explanation and reconciliation of these items. Reconciliation of Reported Net Sales to Organic Net Sales by Segment (1) ($ millions) (1) Organic net sales exclude the impact from acquisitions and/or divestitures and translate the current-period reported sales of subsidiaries whose functional currency is other than the U.S. Dollar at the applicable foreign exchange rates in effect during the comparable prior-year period. Three months ended September 30, Reported Net Sales (U.S. GAAP) Percent Change Impact of Currency Organic Net Sales Growth Rate (Decline) Non-U.S. GAAP (1)2025 2024 Proprietary Products $647.5 $601.4 7.7 % 2.6% 5.1 % Contract-Manufactured Products 157.1 145.5 8.0 % 3.1% 4.9 % Total $804.6 $746.9 7.7 % 2.7% 5.0 % Nine months ended September 30, Reported Net Sales (U.S. GAAP) Percent Change Impact of Currency Organic Net Sales Growth Rate (Decline) Non-U.S. GAAP (1)2025 2024 Proprietary Products $1,830.3 $1,720.6 6.4 % 1.1% 5.3 % Contract-Manufactured Products 438.8 423.8 3.5 % 1.4% 2.1 % Total $2,269.1 $2,144.4 5.8 % 1.1% 4.7 %
Notes to Non-U.S. GAAP Financial Measures RECONCILIATION OF NON-U.S. GAAP FINANCIAL MEASURES (UNAUDITED) See “Notes to Non-U.S. GAAP Financial Measures”, “Safe Harbor Statement” (Slide 3) and today’s press release for an explanation and reconciliation of these items. Reconciliation of Proprietary Products Segment Organic Net Sales by Product Category (1) ($ millions) (1) Organic net sales exclude the impact from acquisitions and/or divestitures and translate the current-period reported sales of subsidiaries whose functional currency is other than the U.S. Dollar at the applicable foreign exchange rates in effect during the comparable prior-year period. Three months ended September 30, Reported Net Sales (U.S. GAAP) Percent Change Impact of Currency Organic Net Sales Growth Rate (Decline) Non-U.S. GAAP (1)2025 2024 HVP Components $390.0 $335.4 16.3 % 3.0% 13.3 % HVP Delivery Devices 99.1 117.5 (15.7)% 1.0% (16.7)% Standard Products 158.4 148.5 6.7 % 3.1% 3.6 % Total Proprietary Products $647.5 $601.4 7.7 % 2.6% 5.1 % Nine months ended September 30, Reported Net Sales (U.S. GAAP) Percent Change Impact of Currency Organic Net Sales Growth Rate (Decline) Non-U.S. GAAP (1)2025 2024 HVP Components $1,061.2 $980.9 8.2 % 1.3% 6.9 % HVP Delivery Devices 296.0 271.6 9.0 % 0.6% 8.4 % Standard Products 473.1 468.1 1.1 % 0.9% 0.2 % Total Proprietary Products $1,830.3 $1,720.6 6.4 % 1.1% 5.3 %
Notes to Non-U.S. GAAP Financial Measures RECONCILIATION OF NON-U.S. GAAP FINANCIAL MEASURES (UNAUDITED) See “Notes to Non-U.S. GAAP Financial Measures”, “Safe Harbor Statement” (Slide 3) and today’s press release for an explanation and reconciliation of these items. Reconciliation of Proprietary Products Segment Organic Net Sales by Market Group (1) ($ millions) (1) Organic net sales exclude the impact from acquisitions and/or divestitures and translate the current-period reported sales of subsidiaries whose functional currency is other than the U.S. Dollar at the applicable foreign exchange rates in effect during the comparable prior-year period. Three months ended September 30, Reported Net Sales (U.S. GAAP) Percent Change Impact of Currency Organic Net Sales Growth Rate (Decline) Non-U.S. GAAP (1)2025 2024 Biologics $329.1 $296.4 11.0 % 2.7% 8.3 % Pharma 182.5 174.3 4.7 % 3.3% 1.4 % Generics 135.9 130.7 4.0 % 1.4% 2.6 % Total Proprietary Products $647.5 $601.4 7.7 % 2.6% 5.1 % Nine months ended September 30, Reported Net Sales (U.S. GAAP) Percent Change Impact of Currency Organic Net Sales Growth Rate (Decline) Non-U.S. GAAP (1)2025 2024 Biologics $886.1 $811.4 9.2 % 1.4% 7.8 % Pharma 561.6 530.8 5.8 % 1.4% 4.4 % Generics 382.6 378.4 1.1 % - % 1.1 % Total Proprietary Products $1,830.3 $1,720.6 6.4 % 1.1% 5.3 %
Notes to Non-U.S. GAAP Financial Measures RECONCILIATION OF NON-U.S. GAAP FINANCIAL MEASURES (UNAUDITED) See “Notes to Non-U.S. GAAP Financial Measures”, “Safe Harbor Statement” (Slide 3) and today’s press release for an explanation and reconciliation of these items. Reconciliation of Reported Net Sales to Organic Net Sales by Geography (1) ($ millions) (1) Organic net sales exclude the impact from acquisitions and/or divestitures and translate the current-period reported sales of subsidiaries whose functional currency is other than the U.S. Dollar at the applicable foreign exchange rates in effect during the comparable prior-year period. Three months ended September 30, Reported Net Sales (U.S. GAAP) Percent Change Impact of Currency Organic Net Sales Growth Rate (Decline) Non-U.S. GAAP (1)2025 2024 Americas $375.3 $356.5 5.3 % 0.1% 5.2 % Europe, Middle East, Africa 361.1 330.1 9.4 % 6.3% 3.1 % Asia Pacific 68.2 60.3 13.1% (1.8)% 14.9 % Total $804.6 $746.9 7.7 % 2.7% 5.0 % Nine months ended September 30, Reported Net Sales (U.S. GAAP) Percent Change Impact of Currency Organic Net Sales Growth Rate (Decline) Non-U.S. GAAP (1)2025 2024 Americas $1,063.9 $957.1 11.2 % (0.3)% 11.5 % Europe, Middle East, Africa 1,017.7 1,000.5 1.7 % 3.1% (1.4)% Asia Pacific 187.5 186.8 0.4 % (1.7)% 2.1 % Total $2,269.1 $2,144.4 5.8 % 1.1% 4.7 %
Notes to Non-U.S. GAAP Financial Measures RECONCILIATION OF NON-U.S. GAAP FINANCIAL MEASURES (UNAUDITED) See “Notes to Non-U.S. GAAP Financial Measures”, “Safe Harbor Statement” (Slide 3) and today’s press release for an explanation and reconciliation of these items. Reconciliation of Reported-Diluted EPS Guidance to Adjusted-Diluted EPS Guidance 2024 Actual 2025 Guidance % Change Reported-diluted EPS (U.S. GAAP) $6.69 $6.75 to $6.80 0.9% to 1.6% Restructuring and other charges 0.02 0.28 Amortization of acquisition-related intangible assets 0.04 0.03 Adjusted-diluted EPS (Non-U.S. GAAP) (1) $6.75 $7.06 to $7.11 4.6% to 5.3% (1) We have opted not to forecast 2025 tax benefits from stock-based compensation in upcoming quarters, as they are out of the Company’s control. Instead, we recognize the benefits as they occur. In the first nine months of 2025, tax benefits associated with stock-based compensation increased adjusted-diluted EPS by $0.05. Any future tax benefits associated with stock-based compensation that we receive in 2025 would provide a positive adjustment to our full-year EPS guidance. In full-year 2024, tax benefits associated with stock-based compensation increased adjusted-diluted EPS by $0.26. See “Full-Uear 2025 Financial Guidance” and “Non-U.S. GAAP Financial Measures” in today’s press release for additional information regarding adjusted-diluted EPS.